FACIO-SCAPULO-HUMERAL DYSTROPHY
Clinical trials for FACIO-SCAPULO-HUMERAL DYSTROPHY explained in plain language.
Never miss a new study
Get alerted when new FACIO-SCAPULO-HUMERAL DYSTROPHY trials appear
Sign up with your email to follow new studies for FACIO-SCAPULO-HUMERAL DYSTROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for FSHD: phase 3 trial of AOC 1020 begins
Disease control Recruiting nowThis study tests an experimental drug called AOC 1020 for facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. About 200 adults with a confirmed FSHD diagnosis who can still walk will receive either the drug or a placebo by I…
Matched conditions: FACIO-SCAPULO-HUMERAL DYSTROPHY
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 26, 2026 09:33 UTC
-
New drug trial targets rare muscle disease
Disease control Recruiting nowThis study tests a new drug called ARO-DUX4 for people with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a condition that causes muscle weakness. About 60 adults and teens will receive either the drug or a placebo to check its safety and how the body processes it. The g…
Matched conditions: FACIO-SCAPULO-HUMERAL DYSTROPHY
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:54 UTC